Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
DERMADIS One line pitch: Dermadis is a late preclinical biotech company developing breakthrough drugs to treat inflammatory skin disorders (both orphan and large market). Market Analysis: As main objective Dermadis intends to bring its lead compound DM107 to clinical validation (Phase I/IIb; exit option one) in the high medical need, orphan indication Netherton syndrome and then achieve market access with 50-70 million product peak sales. Licensing-out/collaborative alliance with large biotech/pharma for the related large market indication atopic dermatitis (AD) will run in parallel upon securing orphan disease POC data. AD and related diseases constitute a developed, multi-billion Euro market. Additionally, Dermadis is in contact with dermato-cosmetics and veterinary medicine companies as supplier of active ingredients. Business Proposition: Dermadis is a key player in a class of emerging drug targets called “Kallikreins”. The company is developing a proprietary biological, DM107, targeting this new family of targets to treat dermatology disorders by controlling specific biological, pathological pathways. DM107 and lead compounds are derived from a proprietary in-house technology platform engineering natural, human protease inhibitors with increased target activity and selectivity. The biomimetics nature of Dermadis' compounds allows also access to the dermato-cosmetics market as active ingredients. COMPANY PROFILE • Website: www.dermadis.com • Activity: Biotech • Contact: KUNDIG Christoph [email protected] • Location: Avenue Marie Curie 218 Archamps Technopole 74160 France Competitive Advantage: • Founded in: 01/03/2010 Good competitive position and differentiated potential: A first-in-class therapeutic biologic as drug to treat (1) a rare disease with high medical need and (2) highly prevalent dermatological conditions with similar pathologies. DM107 has obtained orphan drug status by EMA and FDA. The rational based on strong science has sparked interest from multiple pharma companies after positive POC. The lead product is at the end of preclinical stage with successful manufacturing and no toxicity in primates; clinical program to be initiated. As biomimetics, similar compounds are intended to be marketed as active ingredients in cosmetic conditions. • Employees: 5 Investment Attractiveness: Dermadis offers a proprietary, first-in class advanced biotherapy in an orphan indication without current treatment option/competion. The drug proved pharmacologically active and safe in animal models and the secured orphan drug designation gives access to cost-efficient development and market access and extended market protection. Pharmas with interest in Netherton Syndrome, multiple expanding indications into large markets and anticipated early revenues through dermato-cosmetic collaborations award the project a highly interesting financial potential with limited risk based on different exit options and early decisive milestones. IP Situation: Robust intellectual property condition (2 patents) with long duration of exclusivity (orphan designation): (1) Patent of use: Use of serine protease inhibitors in the treatment of skin diseases, WO/2009/093119A2. Assignees: Dermadis SAS and INSERM. Status: Granted (EP, JP) and Pending (2) Product patent: Inhibitor proteins of a protease and use thereof, WO/2004/087912. Assignee: University of Lausanne, Switzerland. Dermadis holds exclusive, world-wide license for use in dermatology Status: Granted • Management: Kündig Christoph Managing Director and CSO Dupuy Patrick Medical Director Ferreira Sandra Operations & Administration Officer • Financial information (€): - Company stage: late preclinical - Capital raised to date: 4.8 M Euro - Monthly burn rate: - Capital seeking and date: 3.5 M Euro (exit option 1) • Investors: Private Investors, ready for participation later investment round, BPI • Referred by: